An ongoing trial (NCT02632708) is assessing the safety and the efficacy of ivosidenib and enasidenib in combination with induction and consolidation chemotherapy in patients with de novo IDH1- and IDH2-mutated AML. This evidence concerns the gene IDH2 and acute myeloid leukemia.